Danaher will pay $24 a share for Cambridge, England based Abcam, according to a statement Monday. The transaction, which includes debt and acquired cash, is seen closing in mid-2024, and Danaher expects to fund it using cash and proceeds from issuing commercial paper.
Sometimes called the “Amazon of antibodies,” Abcam provides scientists with a variety of laboratory products including the immune ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.